PTO/SB/25 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER

Docket Number (Optional) OP/4-30341B

In re Application of: Kis et al.	RECEIVED					
Application No.: 10/016,361						
Filed: December 10, 2001	MAR 0 9 2004					
For: Autoclavable Pharmaceutical Compositions Containing a Chelatin	g Agent 5 5 255.					
The owner*, Novartis AG, of100_ percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number09/619.349, filed on _July 19, 2000, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.						
Check either box 1 or 2 below, if appropriate.	-					
1. For submissions on behalf of an organization (e.g., coetc.), the undersigned is empowered to act on behalf	orporation, partnership, university, government agency, of the organization.					
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.						
2. The undersigned is an attorney or agent of record.	Signature Date					
	Susan Hess					
	Typed or printed name					
	(862) 778-7859					
	Telephone Number					
I	· ciopilotto i tambo.					

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/25 (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER

Docket Number (Optional)

OP/4-30341B

In re Application of: Kis et al.

Application No.: 10/016,361 Filed: December 10, 2001

MAR 0 9 2004

For: Autoclavable Pharmaceutical Compositions Containing a Chelating Agent

The owner*, Novartis AG _____, of __100_ percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number __10/134.795 _____, filed on April 29, 2002 _____, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check e	ither	box	1	or	2	below,	if	ar	рго	priate	

1	\neg	For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency,
г		etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. The undersigned is an attorney or agent of record.

Signature

Susan Hess
Typed or printed name

(862) 778-7859

Telephone Number

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/26 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Docket Number (Optional)

OP/4-30341B

In re Application of: Kis et al.	RECEIV	ED		
Application No.: 10/016,361				
Filed: December 10, 2001	MAR 09 2	2004		
For: Autoclavable Pharmaceutical Compositions Containing a Chelating	Agent			
The owner*, Novartis AG, of 100 disclaims, except as provided below, the terminal part of the stat which would extend beyond the expiration date of the full statu shortened by any terminal disclaimer, of prior Patent No. 6,455,5 so granted on the instant application shall be enforceable only commonly owned. This agreement runs with any patent granted its successors or assigns.	tory term defined in 35 U.S.C. 154 and 47	instant application, d 173, as presently ees that any patent the prior patent are		
In making the above disclaimer, the owner does not dis application that would extend to the expiration date of the full sprior patent, as presently shortened by any terminal disclaime maintenance fee, is held unenforceable, is found invalid by a whole or terminally disclaimed under 37 CFR 1.321, has all claim is in any manner terminated prior to the expiration of its ful disclaimer.	statutory term as defined in 35 U.S.C. er, in the event that it later: expires to court of competent jurisdiction, is statums canceled by a reexamination certification.	154 and 173 of the for failure to pay a utorily disclaimed in cate, is reissued, or		
Check either box 1 or 2 below, if appropriate.				
1. For submissions on behalf of an organization (e.g., corp etc.), the undersigned is empowered to act on behalf of		ment agency,		
I hereby declare that all statements made herein of my information and belief are believed to be true; and further that the false statements and the like so made are punishable by fine or the United States Code and that such willful false statements me issued thereon.	ese statements were made with the knowing imprisonment, or both, under Section	owledge that willful 1001 of Title 18 of		
2. The undersigned is an attorney or agent of record.	Susandes	3/4/04		
	Signature	Date		
	Susan Hess			
	Typed or printed name			
	(862) 778-7859			
	Telephone Number			
Terminal disclaimer fee under 37 CFR 1.20(d) included.	·			
WARNING: Information on this form may become pr	ublic. Credit card information should not			
be included on this form. Provide credit card inform				
*Statement under 37 CFR 3.73(b) is required if terminal disclaim Form PTO/SB/96 may be used for making this certification. See	er is signed by the assignee (owner). MPEP § 324.			

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.